Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHMT1 | P34896 | 4/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | SHMT2 | P34897 | 3/20 | 0.54 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20255997 | 1.00 | SHMT1 (0.66) | SHMT1ALDH1A1GAALMNAKDM4E | |
| SCHEMBL20255996 | 0.97 | ALDH1A1 (0.69) | SHMT1ALDH1A1GAALMNAKDM4E | |
| SCHEMBL20255553 | 0.96 | SHMT1 (0.68) | SHMT1ALDH1A1GAALMNAKDM4E | |
| SCHEMBL20255500 | 0.93 | SHMT1 (0.73) | SHMT1ALDH1A1GAALMNAKDM4E | |
| SCHEMBL21560156 | 0.93 | SHMT1 (0.73) | SHMT1ALDH1A1GAALMNAKDM4E | |
| SCHEMBL21560091 | 0.93 | SHMT1 (0.64) | SHMT1ALDH1A1GAALMNAKDM4E | |
| SCHEMBL20255836 | 0.93 | SHMT1 (0.64) | SHMT1ALDH1A1GAALMNAKDM4E | |
| SCHEMBL21560310 | 0.92 | KDM4E (0.63) | SHMT1ALDH1A1GAALMNAKDM4E | |
| SCHEMBL20255555 | 0.91 | SHMT1 (0.63) | SHMT1ALDH1A1GAALMNAKDM4E | |
| SCHEMBL21560175 | 0.89 | SHMT1 (0.66) | SHMT1ALDH1A1GAALMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091451-B2 | SHMT inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20190345119-A1 | SHMT INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2019-11-14 | — | — | US | disclosed |
| WO-2018106636-A1 | SHMT INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091451-B2 | SHMT inhibitors and uses thereof | SHMT1, SHMT2, BHMT | SHMT1 1/4885ALDH1A1 189/4885GAA 1802/4885 |
| US-20190345119-A1 | SHMT INHIBITORS AND USES THEREOF | SHMT1, SHMT2, BHMT | SHMT1 1/4885ALDH1A1 189/4885GAA 1802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.